Influenza virus vaccine quadrivalent - Novavax

Drug Profile

Influenza virus vaccine quadrivalent - Novavax

Alternative Names: Influenza virus-like particle vaccine quadrivalent - Novavax; Novavax quadrivalent vaccine; Quadrivalent seasonal virus-like particle (VLP) influenza vaccine (recombinant) - Novavax; Quadrivalent VLP vaccine - Novavax; Recombinant quadrivalent seasonal influenza vaccine - Novavax; VLP-based quadrivalent seasonal influenza vaccine - Novavax

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novavax
  • Class Influenza virus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections

Most Recent Events

  • 06 Aug 2015 Phase-II development is ongoing in Australia
  • 01 Jun 2015 Novavax completes a phase II trial in Influenza virus infections (Prevention, In volunteers) in USA (NCT02307851)
  • 17 Nov 2014 Phase-II clinical trials in Influenza virus infections (Prevention, In volunteers) in USA (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top